ARA-290 16mg
ARA-290 is a synthetic research peptide developed from the B-helix domain region of erythropoietin.
ARA-290 is a synthetic research peptide developed from the B-helix domain region of erythropoietin.
Browse nearby entries from the full catalog, starting with All Peptides.
Start with adjacent compounds, or send one straight to the assistant for a comparison prompt.
Ask AssistantARA-290 is a synthetic research peptide developed from the B-helix domain region of erythropoietin. It binds selectively to the EPOR–CD131 receptor complex and activates the IRR signaling pathway, without stimulating erythropoiesis. Preclinical models show that ARA-290 modulates cytokine activity, endothelial integrity, and neuroimmune signaling, making it a tool for studies of inflammation and tissue protection.
Ostrowski D et al PLoS One, 2017 12(10): e0185838
Jump from this product into the newest URLs, recent updates, and grouped hubs.
Short-acting GHRH analog + GHSR agonist in one vial for studying pituitary axis coordination.
Synthetic fraction of the protein thymosin beta-4, used to investigate actin polymerization and cell migration in recovery contexts.
5-amino-1MQ is a small-molecule research compound that acts as a selective nicotinamide-N-methyltransferase (NNMT) inhibitor.
Acetyl Hexapeptide-3 (Argireline) is a hexapeptide analogue of SNAP-25 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂), developed to modulate vesicle docking and the release of catecholamines by inhibiting SNARE complex formation.
The definitive guide to peptide legality — covering BPC-157, TB-500, and other research peptides. What's legal, what's restricted, and what's changing in 2025-2026.
Comprehensive guide to BPC-157 dosing — injection, oral, and nasal protocols. How to reconstitute, calculate doses, and structure your cycle based on commonly reported approaches.
Supporting documents typically expected alongside the product profile.
This page is compiled from publicly available research material and normalized for browsing inside the catalog.